In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp.
Fifty-four isolates of Campylobacter jejunii, 91 isolates of Yersinia spp. and 56 isolates of Clostridium difficile, recovered from stools of patients with diarrhoea or other intestinal disturbances and from stools of asymptomatic patients receiving antibiotic therapy, were tested in vitro for susceptibility to rifaximin, rifampicin and neomycin. The in vitro antibacterial activities were found to be comparable against the aerobic bacterium; on the contrary, against microaerophilic and anaerobic bacteria rifaximin and rifampicin were much more effective than neomycin.
Ripa
S
S
Department of Cellular Biology, University of Camerino, Italy.
Mignini
F
F
Prenna
M
M
Falcioni
E
E
D002167:Campylobacter / Q000187:drug effects*; D003013:Clostridium / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D009355:Neomycin / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology; D012294:Rifamycins / Q000494:pharmacology*; D000078262:Rifaximin; D015007:Yersinia / Q000187:drug effects*
D012294:Rifamycins; D009355:Neomycin; D000078262:Rifaximin; D012293:Rifampin